InsiderStreet Equity Research

Produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation for any investor. Do not rely on it for any investment decision.

Last Close

$156.19

2026-10-16

Market Cap

$193.7B

Volume

7.8M

52-Wk High

$160.51

52-Wk Low

$114.02

Trailing PE

-60.1

P/S

6.36

Gross Margin

79.6%

Net Margin

-10.6%

ROE

-16%

ROIC

-4%

Piotroski

5/9

Altman Z

3.7

1-Yr Return

+33.4%

5-Yr Return

+216.2%

Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.

SectorHealthcareIndustryDrug Manufacturers - GeneralExchangeNASDAQMarket Cap$193.7BEmployees17,000 (SEC-filed)CEODaniel O'DayIPO1992-01-22CountryUS

333 Lakeside Drive, Foster City, CA 94404 · Tel 650 574 3000 · gilead.com

INSIDERSTREET SCORE44 / 100Street mean $148.11 (9 analysts, last qtr) — their number, not ours

INSIDER CONSENSUS SIGNALROUTINE SELLING — LOW SIGNAL$31M sold / 6 mo, zero open-market buys

1 Year vs S&P 500 · GILD +33.4% · S&P 500 +15.9% · spread +17.5pp

7 Years vs S&P 500 · GILD +216.2% · S&P 500 +189.9% · spread +26.4pp

Both charts indexed to 100 at the start of their window and drawn on a single shared scale, so the gap to the benchmark is the gap you see. Adjusted closes throughout.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

INSIDERSTREET
SCORE44of 100

Score Breakdown

Profitability	20/100
Growth	37/100
Momentum	38/100
Quality	32/100
Earnings Quality	26/100
Balance Sheet	20/100
Value	27/100
Risk (safety)	80/100
Overall	43.8/100

Each component is a diagnostic reading on its own 0-100 scale. The overall score is computed separately from the underlying financials and is not the average of the rows above — components are not equally weighted and three of them (Momentum, Value, Risk) are derived partly from price rather than from the business.

Peer Comparison — IS Score

Symbol	IS Score
PFE	46
AMGN	67
AZN	71
NVS	65
BMY	68
MRK	49
GILD	44

IS Score Trend — quarterly

14 quarters, 23 Q1 to 26 Q2. Peak 78 in 25 Q2, latest 44 — -34 since. Dropped below the 55 line in 26 Q2, at 44. Fell in 3 of the last 4 quarters. Dashed line marks 40 on the 0-100 scale.

BUSINESS QUALITY44 / 100IS Score 43.8 / 100 · -34.4 from peak of 78

Fundamental factor model, quarterly. Measures how the business is doing - not where the price is going.

PRICE STRUCTUREBULLISHTechnical Score 84 / 100 · Power +67 · 20 of 22 indicator votes bullish

Vote share across trend, momentum, volume, volatility and pattern families. Describes where the price is, not where it is going.

These two disagree — business quality 44, price structure 84 out of 100, so the price reads better than the business does. We publish the disagreement rather than resolving it: they answer different questions, and the gap between them is information, not an error.

Trigger	Where it stands now	What it would mean
IS Score reaches 55 and holds two consecutive quarters	now 43.8	would move us up one band
IS Score stops falling - one quarter higher than the prior	last four: 75 → 75 → 77 → 44	the direction matters more than the level
Technical vote share back above 50%	now 100%	price structure no longer broken
Institutional holder count rises two quarters running	peak 2,331 → now 2,299	fewer institutions willing to hold is our clearest warning

We publish these so the view can be shown to be wrong. If none of them move and our reading does, we owe you an explanation.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

This page is InsiderStreet's own reading, produced from the data in the rest of this document. It is not a price target and not investment advice. Analyst consensus and street price targets appear later under their own heading and are the street's numbers, not ours.

Site Convergence Score3 of 4top 4% of 29,420 symbols

Sources Aligned— of 3independent disclosures

Congress (180d)5 buys2026-05-06

Insider Buys (180d)0none disclosed

ETF Funds (30d)1979 up / 1613 downnet +366 funds

Institutions Added (13F)-32managers opening or increasing

Congressional and insider figures are disclosed purchases in the trailing 180 days; ETF figures are COUNTS OF FUNDS whose holding changed in 30 days, not dollars. Coincidence of separate disclosures, not coordination. An absent source means nothing qualifying was disclosed in its window.

Institutions holding — 12 quarters

Peak 2,331 · latest 2,299 (-32 from peak).

Quarter	Holders	13F shares	Value	Reported own%
2026 Q2	2,299	1120.1M	$135.8B	90.1%
2026 Q1	2,331	1074.0M	$144.6B	86.4%
2025 Q4	2,227	1103.9M	$130.3B	88.8%
2025 Q3	2,034	1056.7M	$113.4B	85.0%
2025 Q2	2,032	1077.4M	$115.8B	86.7%
2025 Q1	2,028	1065.1M	$116.7B	85.7%
2024 Q4	1,892	1064.2M	$96.7B	85.6%
2024 Q3	1,725	1044.2M	$86.3B	84.0%
2024 Q2	1,690	1038.2M	$70.4B	83.5%
2024 Q1	1,728	1041.3M	$74.6B	83.8%
2023 Q4	1,784	1046.4M	$82.9B	84.2%
2023 Q3	1,688	1041.3M	$76.7B	83.8%

How to read ownership above 100%. A 13F reports the positions a manager has investment discretion over, and where two or more managers share discretion over the same block, each one reports it. Summed across filers, the total can therefore exceed the shares actually outstanding without anything being wrong. We publish the figure as filed rather than netting it down, and flag separately any quarter where the arithmetic is not merely high but impossible.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Insider	Role	Date	Type	Shares	Value	Post-Txn Owned
Mercier Johanna	Chief Comm & Corp Aff Officer	2026-10-15	SELL	3,000	$0.47M	113,684
Dickinson Andrew D	Chief Financial Officer	2026-10-15	SELL	3,000	$0.47M	161,096
O'Day Daniel Patrick	director, Chairman & CEO	2026-10-01	SELL	12,000	$1.77M	569,683
O'Day Daniel Patrick	director, Chairman & CEO	2026-10-01	SELL	3,000	$0.45M	566,683
Burkhart Erin	SVP, Controllership	2026-09-22	EXERCISE	2,223	—	2,223
Burkhart Erin	SVP, Controllership	2026-09-22	TAX W/H	768	$0.12M	1,455
Burkhart Erin	SVP, Controllership	2026-09-22	EXERCISE	2,223	—	9,022
Dickinson Andrew D	Chief Financial Officer	2026-09-15	SELL	3,000	$0.44M	164,096

6-mo decomposition (Form 4)	Txns	Shares	Value	Signal weight
S — Open-market sales	52	226,000	$31.2M	Counted
M — Exercises (paired A/D)	24	148,706	$4.8M	None — mechanics
F — Tax withholding	18	36,612	$5.2M	None — compensation
P — Open-market purchases	0	0	$0	Counted — none occurred

Monthly Net Insider Flow (000 shares)

Net of acquisitions minus dispositions, all Form 4 types.

Signal Summary

SignalRoutine Selling — Low Signal

Open-Market Sells$31.2M52 txns / 6 mo

Open-Market Buys$0.0M0 txns / 6 mo

ClusterNone active3+ insiders / 21 days

Filed	Filer	Shares registered	Est. proceeds
2026-10-15	Andrew Dickinson	3,000	$0.5M
2026-10-15	Johanna Mercier	3,000	$0.5M
2026-09-15	Andrew Dickinson	3,000	$0.4M
2026-09-15	Johanna Mercier	3,000	$0.4M
Trailing 12 mo	46 filings	686,752	$93M

Filed	Form	Reporting person	% of class	Shares
2026-04-29	SCHEDULE 13G	Vanguard Capital Management	7.51%	93.3M sh
2026-03-26	SCHEDULE 13G/A	The Vanguard Group	—	exit/reporting change
2026-02-05	SCHEDULE 13G	Abigail P. Johnson	5.30%	65.5M sh
2025-05-13	SCHEDULE 13G/A	Capital World Investors	4.30%	53.8M sh

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Member	Chamber	Trade	Size band	Traded	Disclosed
Ro Khanna	House	SELL	$1,001 - $15,000	2026-08-10	2026-09-07
Ro Khanna	House	SELL	$1,001 - $15,000	2026-07-07	2026-08-12
Jared Moskowitz	House	BUY	$1,001 - $15,000	2026-05-06	2026-06-22
John Boozman	Senate	SELL	$1,001 - $15,000	2025-04-16	2025-05-14
John Boozman	Senate	SELL	$1,001 - $15,000	2025-04-16	2025-05-14
John Boozman	Senate	SELL	$1,001 - $15,000	2025-04-16	2025-05-13

House 12-Mo12 trades8 purchases

Senate 12-Mo0 tradesNone purchases

CoverageSTOCK Act filings30-45 day disclosure lag

13F Filers (last complete Q)2,331

13F Shares1.07B86.4% of shares out

New / Closed248 / 104positions, QoQ

Increased / Reduced863 / 896positions, QoQ

Put/Call (13F)0.94option positions

Free Float99.8%1.24B sh

2.8 · Largest Reporting 13F Managers

Manager	Shares	Value
Assenagon Asset Management S.A.	1.6M	$233M
Confluence Investment Management L	791,297	$118M
Bailard, Inc.	734,720	$110M
Vontobel Holding Ltd.	702,082	$105M
Fjarde Ap-Fonden /Fourth Swedish N	558,657	$83M
Mn Services Vermogensbeheer B.V.	368,039	$55M

EDGAR 13F holdings as of 2026-09-30; filer values normalized to dollars.

2.9 · Top ETF & Fund Ownership

Fund	Weight	Position
VITSX	0.3%	$5.9B
VTI	0.3%	$5.9B
VSMPX	0.3%	$5.9B
VTSAX	0.3%	$5.9B
VFFSX	0.3%	$4.9B
VFINX	0.3%	$4.9B

13F Filers Holding GILD — quarterly

Institutional Put/Call — quarterly

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Daily short-sale volume as % of volume reported in FINRA's short-sale file — a flow measure, not short interest; dashed = 50-day average.

Latest Session49.5%2026-10-15

20-Day Avg42.7%50-day 39.5%

TrendRising20d vs 50d

By Market CenterQ: 50% · N: 49% · B: 42%latest session

Weekly Notional ($B)

Where GILD Trades in the Dark

ATS Venue (4-wk)	Shares	Avg trade
Incr Intelligent Cross Llc	7.7M	57 sh
Ubsa Ubs Ats	6.9M	67 sh
Ebxl Level Ats	4.7M	40 sh
Pure Purestream	4.4M	51 sh
Sgmt Sigma X2	3.9M	57 sh
Mstx Ms Trajectory Cross (Ats-1)	2.9M	63 sh

Where a dollar of Gilead Sciences, Inc. revenue goes. All values FY2025 filings, live.

Region	Revenue	Share
UNITED STATES	$20.9B	71%
Europe	$5.1B	17%
Other International	$3.5B	12%

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

GILD (live moat model)Peer median: PFE · AMGN · AZN · NVS · BMY

Component scores from the live moat model. Peer median illustrative.

Moat score 66/100 — Narrow; primary source Intangible Assets.

3.8 · Employees (SEC filings)

Officer	Title
Daniel O'Day	Chairman & Chief Executive Officer
Dietmar Berger	Chief Medical Officer
Johanna Mercier	Chief Commercial & Corporate Affairs Officer
Andrew D. Dickinson	Executive VP & CFO

Revenue ($B)

EPS ($) — GAAP diluted actual, street-basis estimate

Actual bars are GAAP diluted EPS from the filed income statement; the lighter forward bars are street-basis consensus. The two are different measures and are not comparable quarter to quarter.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Quarterly EPS — Actual vs. Consensus

Beats (>2%)5 of 6recent quarters

Avg Surprise+6.0%

Next Report2026-10-29

Income Quality2.59OCF ÷ net income

Beat Rate—%0 of 0 quarters

Current Streak0longest 0

Avg EPS Surprise—%median —%

Surprise Trend—last 4 vs prior 4

Period	EPS est.	EPS actual	EPS surprise	Rev est. ($M)	Rev actual ($M)	Rev surprise

Announcement dates to . Consensus as it stood at each report. Revenue surprise shown where both estimate and actual are filed. A beat record is history, not a forecast.

Profit Margins (%)

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Revenue by Segment — Stacked

Live segmentation data.

YoY Growth Heatmap — Income Lines

YoY growth	FY21	FY22	FY23	FY24	FY25
Revenue	+10.6%	-0.1%	-0.6%	+6.0%	+2.4%
Gross profit	+2.9%	+4.4%	-4.7%	+9.1%	+13.4%
Operating income	+143.6%	-26.1%	+3.8%	-78.1%	+611.0%
Net income	+4961.0%	-26.2%	+23.4%	-91.5%	+1672.9%

$B · FY ends	FY21	FY22	FY23	FY24	FY25
Revenue	27.3	27.3	27.1	28.8	29.4
Cost of revenue	6.6	5.7	6.5	6.3	3.9
Gross profit	20.7	21.6	20.6	22.5	25.5
R&D expense	4.6	5.0	5.7	5.9	5.7
SG&A expense	5.2	5.7	6.1	6.1	5.7
Operating income	9.9	7.3	7.6	1.7	11.8
EBITDA	11.3	8.9	10.5	4.4	10.8
D&A	2.1	2.1	2.7	2.8	0.0
Pretax income	8.3	5.8	6.9	0.7	9.8
Income tax	2.1	1.2	1.2	0.2	1.3
Net income	6.2	4.6	5.7	0.5	8.5
Diluted EPS ($)	4.93	3.64	4.50	0.38	6.78
Diluted shares (M)	1,262	1,262	1,258	1,255	1,255

Operating CF$10B

CapEx$1B

Free cash flow$9B

SBC$0B

Buybacks$2B

Net cash change$-2B

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Balance Sheet — Full

$B	FY22	FY23	FY24	FY25
Cash & equivalents	5.4	6.1	10.0	7.6
ST investments	1.0	1.2	1.6	3.0
Receivables (net)	4.8	4.7	4.4	4.9
Total current assets	14.4	16.1	19.2	19.9
PP&E (net)	5.5	5.3	5.4	5.6
Goodwill + intangibles	37.2	34.8	28.3	25.3
Total assets	63.2	62.1	59.0	59.0
Accounts payable	0.9	0.6	0.8	0.0
Short-term debt	2.3	1.8	1.8	0.0
Deferred revenue	0.0	0.0	0.0	0.0
Total current liabilities	11.2	11.3	12.0	11.8
Long-term debt	23.0	23.2	24.9	24.6
Total liabilities	42.0	39.4	39.7	36.4
Shareholders' equity	21.2	22.7	19.2	22.6

Cash Flow Statement — Full

$B	FY22	FY23	FY24	FY25
Net income	4.6	5.7	0.5	8.5
D&A	2.1	2.7	2.8	2.8
Stock-based compensation	0.6	0.8	0.8	0.0
Working capital change	(1.8)	(2.3)	(0.9)	(3.9)
Operating cash flow	9.1	8.0	10.8	10.0
Capital expenditures	(0.7)	(0.6)	(0.5)	(0.6)
Investing cash flow	(2.5)	(2.3)	(3.4)	(4.8)
Buybacks	(1.4)	(1.0)	(1.2)	(1.9)
Dividends paid	(3.7)	(3.8)	(3.9)	(4.0)
Debt issuance / (repay)	(1.5)	(0.3)	1.5	(1.8)
Financing cash flow	(6.5)	(5.1)	(3.4)	(7.7)
Free cash flow	8.3	7.4	10.3	9.5

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Balance Sheet Structure ($B)

Cash Generation vs Capex ($B)

Left: what the balance sheet is made of — the gap between the assets bar and the liabilities bar is book equity. Right: whether the capex bar is covered by the operating-cash bar; where it is not, the difference was funded externally and free cash flow goes negative.

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
PROFITABILITY
ROE	31.7%	21.7%	25.7%	2.3%	40.6%	-16%
ROA	9.1%	7.0%	9.0%	0.8%	14.4%	-6.6%
ROIC	18.0%	14.4%	15.3%	3.3%	26.2%	-3.7%
Gross margin	75.8%	79.3%	76.0%	78.3%	86.7%	79.6%
Operating margin	36.3%	26.9%	28.0%	5.8%	40.1%	-4.9%
Net margin	22.8%	16.8%	20.9%	1.7%	28.9%	-10.6%
EBITDA margin	41.5%	32.4%	38.7%	15.4%	36.7%	4.4%
FCF margin	39.6%	30.6%	27.4%	35.8%	32.1%	—
VALUATION
P/E	12.67	21.26	16.79	235.67	18.07	-60.1
P/B	3.74	4.60	4.16	5.85	6.80	16.4
P/S	2.89	3.58	3.51	3.93	5.22	6.36
P/FCF	7.30	11.70	12.81	10.98	16.27	14.7
EV/EBITDA	8.74	13.16	10.75	28.92	12.35	162.5
EV/Revenue	3.63	4.27	4.16	4.46	5.70	7.1
Earnings yield	7.9%	4.7%	6.0%	0.4%	5.5%	-1.67%
FCF yield	13.7%	8.5%	7.8%	9.1%	6.1%	6.82%

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
LEVERAGE & SOLVENCY
Current ratio	1.27	1.29	1.43	1.60	1.68	1.27
Quick ratio	1.13	1.15	1.27	1.45	1.31	1.09
Debt / equity	1.27	1.19	1.09	1.38	1.09	2.22
Debt / assets	39.3%	39.9%	40.2%	45.3%	41.7%	53.2%
Net debt / EBITDA	1.78	2.13	1.69	3.41	1.03	17.29
Interest coverage	9.27	7.22	8.27	1.71	10.56	—

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
EFFICIENCY
Asset turnover	0.40	0.42	0.43	0.47	0.50	0.62
Receivables turnover	5.82	5.89	5.75	6.33	6.31	6.0
DSO (days)	63	62	64	58	58	61
DPO (days)	43	52	41	40	24	40
Cash conversion cycle	111	111	115	119	211	136
GROWTH (YoY)
Revenue growth	10.6%	-0.1%	-0.6%	6.0%	2.4%	—
Net income growth	4961.0%	-26.2%	23.3%	-91.5%	1672.9%	—
EPS growth	4948.9%	-26.3%	24.1%	-91.5%	1681.4%	—
FCF growth	43.7%	-22.8%	-11.1%	38.9%	-8.2%	—
PER SHARE ($)
EPS (diluted, TTM)	4.93	3.63	4.51	0.38	6.79	-2.61
Book value / share	16.69	16.80	18.18	15.35	18.05	9.45
Revenue / share	21.64	21.58	21.59	22.84	23.50	24.50
FCF / share	8.56	6.60	5.91	8.19	7.55	10.62
Cash / share	5.17	5.05	5.78	9.19	8.46	2.56
SHAREHOLDER RETURN & SCORES
Buyback yield	0.7%	1.4%	1.1%	1.0%	1.2%	0.92%
Altman Z-Score	2.25	2.59	2.76	2.71	3.80	3.7
Piotroski F-Score	6	6	7	6	9	5/9
Beneish M-Score	-2.76	-2.94	-2.59	-3.48	-2.49	-4.14

Model	Score	Zone	Note
Piotroski F-Score	5 / 9	Middling
Altman Z-Score	3.7	Safe (>2.99)	Safe
Income quality	2.59	Cash-backed	OCF ÷ net income
Beneish M-Score	-4.14	Non-manipulator	vs −2.22 threshold

DuPont Decomposition (TTM)	Value
Tax burden	1.66
Interest burden	1.37
Operating margin	-4.7%
Asset turnover	0.58×
Financial leverage	3.34×
= ROE	-21%

Growth Quality (live)	Value
Revenue stability	0.88
Earnings stability	0.35
Earnings persistence	0.20
Revenue CAGR 3y	3.6%
EPS CAGR 3y	—
FCF CAGR 3y	13.9%

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Buyback Yield0.92%

Dividend Yield2.08%

Total Shareholder Return3.31%cash yield

SBC / Revenue1.5%dilution pressure

Company	Mkt cap	P/E	ROE	Net margin	Rev growth	Piotroski	1-yr ret
PFE	$168.6B	39.1	5%	-1.6%	-0.2%	7/9	+24.2%
AMGN	$233.8B	26.7	91%	23.6%	+9.2%	8/9	+50.3%
AZN	$256.5B	24.7	22%	16.3%	+8.6%	9/9	-1.5%
NVS	$286.3B	22.9	31%	22.7%	+0.8%	5/9	+15.1%
BMY	$122.1B	13.2	47%	25.6%	+3.1%	8/9	—
MRK	$360.1B	115.8	7%	-8.0%	+4.5%	4/9	—
ABBV	$504.4B	80.4	-206%	21.3%	+10.4%	7/9	—
JNJ	$615.9B	38.7	26%	21.9%	+8.1%	7/9	—

1-yr returns computed from adjusted price history; peers without a tracked series show —.

Buy

58 Analysts

Str Sell (0)Sell (1)Hold (19)Buy (38)Str Buy (0)

Mean Target (qtr)$148.119 targets

Target vs. Price-5.2%last-quarter mean

Next Report2026-10-29street $2.18

Consensus estimates	Revenue mean	High / Low	EPS mean	High / Low	# EPS est.
FY2026	$30.73B	$30.96B / $30.50B	$-0.41	$-0.27 / $-0.57	16
FY2027	$32.85B	$33.49B / $31.80B	$9.99	$11.53 / $9.44	16
FY2028	$34.63B	$37.59B / $32.25B	$10.78	$12.24 / $9.15	10

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Street Price Target — Trajectory

Window	Avg Target	vs. Price	# Targets
Last Month	$149.33	-4.4%	3
Last Quarter	$148.11	-5.2%	9
Last Year	$152.17	-2.6%	48
All Time	$117.01	-25.1%	108

Rolling mean of published targets vs. last close $156.19. Aggregated from StreetInsider, Benzinga, Pulse 2.0.

Third-Party Composite Rating

C-

DCF

4/5

ROE

1/5

ROA

1/5

Debt/Eq

1/5

P/E

1/5

P/B

1/5

Independent quant composite as of 2026-10-16; components scored 1–5 (5 best). Shown for contrast with the InsiderStreet Score — methodologies differ.

GILD +33.4% vs S&P 500 +15.9% — spread +17.5pp

Sector — XLV +24.2%

Peer Set — indexed to 100

All series indexed to 100 at the start of the window, adjusted closes.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Candlesticks with SMA 20/50 overlay, Bollinger (20,2σ) band, volume, and Wilder RSI(14) — computed from live daily OHLCV.

Moving Average	Value	Distance	% Distance	Signal
SMA 20	$149.97	+6.22	+4.15%	Above
SMA 50	$146.67	+9.52	+6.49%	Above
SMA 200	$137.91	+18.28	+13.26%	Above
EMA 9	$152.01	+4.18	+2.75%	Above
EMA 21	$149.90	+6.29	+4.20%	Above
EMA 50	$146.16	+10.03	+6.86%	Above
EMA 200	$136.01	+20.18	+14.84%	Above

Series and readings from the nightly technical-indicator history — identical data to the site's ribbon chart. Supertrend segments colored by direction.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

TECHNICAL VERDICTBULLISHPower Score +6720 of 22 indicator votes bullish

Family Scores (site weights)

Trend 30%100

Momentum 25%100

Volume 20%56

Volatility 10%100

Patterns 15%50

This Week100% bullishof 11 price-based votes

4 Weeks Ago100%+0 pts since

12 Weeks Ago45%+55 pts since

ReadStabilizingweek-over-week trajectory

Price vs SMA 20$149.97

Price vs SMA 50$146.67

Price vs SMA 200$137.91

EMA 9/21 Cross152.0/149.9

SMA 50/200Golden

ADX DirectionADX 24

Supertrend$146

Parabolic SAR$145

SMA Slope0.300

RSI63.5

Stochastic K/D85/78

StochRSI K/D94/80

Williams %R-24

CCI174

TSI vs Signal15.9

CMO27.1

ROC7.91%

OBV SignalDistrib

Chaikin MF0.010

MFI44

Force Index6M

Elder Ray Bull7.61

RSI (14)30 oversold · 70 overbought

Stochastic %Kvs %D 78

Money Flowvolume-weighted RSI

ADXtrend strength · <20 weak

Williams %Rinverted scale

Level	Value	Level	Value
Pivot / R1 / R2	$157.97 / $159.91 / $162.46	S1 / S2	$155.42 / $153.48
Bollinger (20,2)	$143.00 – $156.94	Squeeze	Off
52-wk range	$113.27 – $160.51	Off 52-wk high	-2.7%
ATR (14)	$3.79 (2.4%)	Historical vol	25.0%

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

+3.9%Jan65%

-1.3%Feb45%

+1.3%Mar52%

-0.8%Apr40%

-0.3%May45%

+2.2%Jun70%

+2.1%Jul60%

+0.2%Aug40%

+1.6%Sep50%

+3.4%Oct65%

+1.1%Nov55%

-0.5%Dec30%

Sample: 20 years — treat short histories as suggestive, not statistical.

Computed from live weekly prices	GILD	S&P 500
Weekly volatility (σ, 1y)	3.39%	1.83%
Best / worst week (1y)	+8.6% / -5.3%	—
Max drawdown (5y, monthly)	-22.5%	—
1-week VaR (95%)	-4.1%	—
Beta (5y)	0.35	1.00

GILD EQUITY WEATHER (LIVE)CLOUDY · +9

Trend+43

Momentum+56

Volume-28

Volatility-60

Breadth-30

MARKET REGIME (2026-10-16)NEUTRAL

VIX19.99Normal

Dow TheoryConfirmed Bearish

SPY / QQQ TSI7.2 / 4.7trend strength

Sector Strength46/100breadth average

Average sentiment of 376 stories, weekly buckets, −1 to +1.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Overall+9.3+18.8 vs industry

Trend+43.0+47.1 vs industry

Momentum+55.8+46.0 vs industry

Volume-27.7-44.3 vs industry

Reading	GILD	Drug Manufacturers - General n=150	Healthcare n=5,272	All US symbols n=70,435
Overall	+9.3	-9.5	-24.0	-20.5
Trend	+43.0	-4.1	-25.6	-21.3
Momentum	+55.8	+9.9	-28.5	-15.8
Volume	-27.7	+16.6	-25.0	-3.8

Trend, momentum and volume are computed per company. Volatility and breadth are market-regime values shared by every symbol in the universe, so they are reported once under Market Regime rather than compared here - a company cannot differ from its sector on a constant.

Executive	Total comp	Structure
Daniel P. O’Day Chairman and Chief Executive	$28.4M	71% equity+incentive
Dietmar Berger, M.D., Ph.D. Chief Medical Of	$13.9M	62% equity+incentive
Johanna Mercier Chief Commercial and Corpora	$9.3M	72% equity+incentive
Andrew D. Dickinson Chief Financial Officer	$8.8M	72% equity+incentive
Deborah H. Telman Former Executive Vice Pres	$5.0M	61% equity+incentive

Pillar (live disclosure scores)	Score
Environmental	50
Social	58
Governance	54
Composite ESG	54

Composite ESG Trend

Filed	8-K contents	Items
2026-08-04	Earnings Release; Exhibits	2.02,9.01
2026-05-20	Material Agreement; Financial Obligation; Other Events; Exhibits	1.01,2.03,8.01,9.01
2026-05-04	Shareholder Vote; Exhibits	5.07,9.01
2026-04-28	Regulation FD; Other Events; Exhibits	7.01,8.01,9.01
2026-02-23	Entry into Material Definitive Agreement; Regulation FD Disclosure; Fi	1.01,7.01,9.01
2026-02-10	Results of Operations and Financial Condition; Financial Statements an	2.02,9.01
2025-11-19	Departure/Election of Directors; Appointment of Officers	5.02
2025-10-30	Results of Operations and Financial Condition; Financial Statements an	2.02,9.01

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Methodology. Every figure originates in InsiderStreet's production data layer and is computed deterministically by the same engines that power insiderstreet.ai. This factsheet contains no model-written text. Sections without underlying data are omitted rather than estimated.

DISCLOSURES. This document is produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation tailored to any person. Data is sourced as of the dates shown and may no longer be current. InsiderStreet.ai is not a registered investment adviser or broker-dealer. Investing involves risk, including loss of principal. Past performance does not guarantee future results. Do not make any investment decision based on this document. © 2026 InsiderStreet.ai — all rights reserved. Redistribution prohibited.

Data domain	Source	Coverage for this report
Price & volume	market_db.historical_prices	52 rows
Fundamentals	income_statements_annual	6 rows · 2020 to 2025
Reported vs consensus	fact/earnings_calendar	24 rows · 2020-10-28 to 2026-08-04
Analyst estimates	dim/forward_estimates	3 rows · 2026-12-31 to 2028-12-31
Institutional ownership (13F)	holdings_db.institutional_ownership_summary	114 rows · 1987 to 2026
Insider transactions (Form 4)	edgar/form4	12 rows · 2026-09-10 to 2026-10-15
Proposed sales (Form 144)	edgar/form144	1 record
Beneficial ownership (13D/G)	edgar/13dg	4 rows · 2025-05-13 to 2026-04-29
Short-sale volume (FINRA)	edgar/short_volume_daily	60 rows · 2026-07-23 to 2026-10-15
Dark pool (ATS, tier 1)	edgar/darkpool_weekly	12 rows · 2026-06-15 to 2026-08-31
ETF & fund holding	etf_holdings_changelog (30d)	1 record
Peer set	stock_peers_dynamic	8 rows
Industry medians	industry_medians	1 record
Congressional trades	congress_db (House + Senate)	1 record
ESG	fact/esg_disclosures	1 record

Method. Every figure in this factsheet is looked up from a named field computed in code. It contains no model-written text.

Not covered. Short interest as a percent of float and days-to-cover are not in this data set — the short-sale figures above are FINRA volume, a flow, and cannot support squeeze or covering analysis. Options positioning and intraday data are also absent. 13F ownership is filed 45 days after quarter end and congressional trades are disclosed on a lag, so both describe a past position, not a current one.

Gilead Sciences, Inc. (GILD)

Gilead Sciences, Inc. (GILD)

Score Breakdown

Peer Comparison — IS Score

IS Score Trend — quarterly

Gilead Sciences, Inc. (GILD)

Institutions holding — 12 quarters

Gilead Sciences, Inc. (GILD)

Monthly Net Insider Flow (000 shares)

Signal Summary

Gilead Sciences, Inc. (GILD)

2.8 · Largest Reporting 13F Managers

2.9 · Top ETF & Fund Ownership

13F Filers Holding GILD — quarterly

Institutional Put/Call — quarterly

Gilead Sciences, Inc. (GILD)

Where GILD Trades in the Dark

Gilead Sciences, Inc. (GILD)

3.8 · Employees (SEC filings)

Gilead Sciences, Inc. (GILD)

Gilead Sciences, Inc. (GILD)

Gilead Sciences, Inc. (GILD)

Balance Sheet — Full

Cash Flow Statement — Full

Gilead Sciences, Inc. (GILD)

Gilead Sciences, Inc. (GILD)

Gilead Sciences, Inc. (GILD)

Gilead Sciences, Inc. (GILD)

Street Price Target — Trajectory

Third-Party Composite Rating

Gilead Sciences, Inc. (GILD)

Gilead Sciences, Inc. (GILD)

Family Scores (site weights)

Gilead Sciences, Inc. (GILD)

Gilead Sciences, Inc. (GILD)

Gilead Sciences, Inc. (GILD)